Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 6 art units • 8 examiners • 0 of 10 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Fate Therapeutics Inc. currently has 11 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 6 distinct art units, indicating that the portfolio covers several specialized biological or chemical classifications. The prosecution involves 9 distinct examiners, which requires the company to manage multiple examiner relationships and varying levels of scrutiny across its 11 pending office actions.
ZHU, JIANJIAN is the busiest examiner for this portfolio, with 3 pending office actions currently under review. This concentration of 3 pending office actions with a single examiner out of the 9 distinct examiners involved suggests that ZHU, JIANJIAN has a significant influence on the company's immediate prosecution success. The remaining pending office actions are spread among the other 9 distinct examiners, highlighting a need for a versatile legal strategy that accounts for the 6 distinct art units where these applications reside. Practitioners should note that the 6 distinct art units may present different examination challenges for the 11 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 4 (40%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 3 | 58.8% | +82.4% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782600 | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS | WESTON, ALYSSA G | 30d overdue |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | — |
| 18250735 | ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL | HOPKINS, SAMANTHA LAKE | — |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782600 | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS | WESTON, ALYSSA G | 30d overdue |
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | FAUST, AMBER KATHLEEN | — |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | — |
| 18250735 | ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL | HOPKINS, SAMANTHA LAKE | — |
| 18250737 | MULTIPLEXED ENGINEERED IPSCS AND IMMUNE EFFECTOR CELLS TARGETING SOLID TUMORS | STOICA, ELLY GERALD | — |
| 18250733 | ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS | SZPERKA, MICHAEL EDWARD | — |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | — |
| 17769651 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1643 | 2 |
| 1641 | 2 |
| 1647 | 1 |
| 1633 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | — | Pending | Oct 16, 2024 |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | 1631 | §102§103 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18250735 | ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL | HOPKINS, SAMANTHA LAKE | 1641 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18250737 | MULTIPLEXED ENGINEERED IPSCS AND IMMUNE EFFECTOR CELLS TARGETING SOLID TUMORS | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18250733 | ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS | SZPERKA, MICHAEL EDWARD | 1641 | §102§112DP | Non-Final OA | — | Pending | Apr 26, 2023 |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | 1643 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2022 |
| 17782600 | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | 30d overdue | Pending | Jun 03, 2022 |
| 17769651 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | 1631 | §103DP | Final Rejection | — | Pending | Apr 15, 2022 |
| 17766513 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | 1631 | §103DPOther | Final Rejection | — | Pending | Apr 04, 2022 |
| 17762693 | MULTI-TARGETING EFFECTOR CELLS AND USE THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §103DP | Non-Final OA | — | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial